Last reviewed · How we verify
sphingosine kinase-2 inhibitor ABC294640 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
sphingosine kinase-2 inhibitor ABC294640 (sphingosine kinase-2 inhibitor ABC294640) — RedHill Biopharma Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| sphingosine kinase-2 inhibitor ABC294640 TARGET | sphingosine kinase-2 inhibitor ABC294640 | RedHill Biopharma Limited | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- sphingosine kinase-2 inhibitor ABC294640 CI watch — RSS
- sphingosine kinase-2 inhibitor ABC294640 CI watch — Atom
- sphingosine kinase-2 inhibitor ABC294640 CI watch — JSON
- sphingosine kinase-2 inhibitor ABC294640 alone — RSS
Cite this brief
Drug Landscape (2026). sphingosine kinase-2 inhibitor ABC294640 — Competitive Intelligence Brief. https://druglandscape.com/ci/sphingosine-kinase-2-inhibitor-abc294640. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab